Pterygium Head Body MMC1: Two Different Surgical Procedures and Their Effect on Endothelial Cell Count.

NCT ID: NCT02641132

Last Updated: 2015-12-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

62 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-09-30

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate changes in endothelial cell count after pterygium surgery with mitomycin C (MMC) 0.02%

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To evaluate the change in endothelial cell count in patients after pterygium surgery with mitomycin C (MMC) 0.02% for 2 minutes in 2 groups.

* The control group: application of MMC after excision of the body of the pterygium without the head
* The study group: application of MMC after excision of the body and the head of the pterygium

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pterygium

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pterygium surgery: Head and body.

Application of Mitomycin C 0.02% after excision of the body and the head of the pterygium.

Group Type EXPERIMENTAL

Mitomycin C 0.02%

Intervention Type DRUG

Pterygium excision with application of mitomycin C

Pterygium surgery

Intervention Type PROCEDURE

Two different procedures- excision of the head and the body and excision of the head only

Pterygium surgery: Body.

Application of Mitomycin C 0.02% after excision of the body only of the pterygium.

Group Type ACTIVE_COMPARATOR

Mitomycin C 0.02%

Intervention Type DRUG

Pterygium excision with application of mitomycin C

Pterygium surgery

Intervention Type PROCEDURE

Two different procedures- excision of the head and the body and excision of the head only

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mitomycin C 0.02%

Pterygium excision with application of mitomycin C

Intervention Type DRUG

Pterygium surgery

Two different procedures- excision of the head and the body and excision of the head only

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males/females \>18 Years old
* Pterygium with indication to operate
* Subjects that are able to sign an informed consent

Exclusion Criteria

* Recurrent Pterygium/suspected tumor lesion
* Patients with endothelial cell diseases
* Patients after anterior segment surgery
* Patients with low compliance
* Patients without judgment ability
* Pregnancy
* Patients participated in another survey
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Meir Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

segev fani

Department of Ophthalmology, Meir medical centre, Kfar saba, Isreal

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sackler school of medicine

Tel Aviv, Israel, Israel

Site Status

Meir medical centre

Kfar Saba, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Fani Segev, MD

Role: CONTACT

Phone: +792526995044

Email: [email protected]

Leena Asalee, MD

Role: CONTACT

Phone: +972543031396

Email: [email protected]

References

Explore related publications, articles, or registry entries linked to this study.

Avisar R, Avisar I, Bahar I, Weinberger D. Effect of mitomycin C in pterygium surgery on corneal endothelium. Cornea. 2008 Jun;27(5):559-61. doi: 10.1097/ICO.0b013e318165b158.

Reference Type BACKGROUND
PMID: 18520505 (View on PubMed)

Bahar I, Kaiserman I, Lange AP, Slomovic A, Levinger E, Sansanayudh W, Slomovic AR. The effect of mitomycin C on corneal endothelium in pterygium surgery. Am J Ophthalmol. 2009 Mar;147(3):447-452.e1. doi: 10.1016/j.ajo.2008.08.035. Epub 2008 Nov 7.

Reference Type BACKGROUND
PMID: 18992871 (View on PubMed)

Avisar R, Apel I, Avisar I, Weinberger D. Endothelial cell loss during pterygium surgery: importance of timing of mitomycin C application. Cornea. 2009 Sep;28(8):879-81. doi: 10.1097/ICO.0b013e3181a3900c.

Reference Type BACKGROUND
PMID: 19654528 (View on PubMed)

Kheirkhah A, Izadi A, Kiarudi MY, Nazari R, Hashemian H, Behrouz MJ. Effects of mitomycin C on corneal endothelial cell counts in pterygium surgery: role of application location. Am J Ophthalmol. 2011 Mar;151(3):488-93. doi: 10.1016/j.ajo.2010.09.014. Epub 2011 Jan 13.

Reference Type BACKGROUND
PMID: 21236405 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0091-13-MMC

Identifier Type: -

Identifier Source: org_study_id